Clinical Trial Update: A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety, efficacy, and optimal dosage of K-161 in moderate to severe dry eye disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• K-161

Snippet

Sponsor: Kowa Research Institute, Inc. | Conditions: Dry Eye Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-03-15